Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering of T cell engaging bispecific protein able to selectively target cancer cells with a high-frequency mutation in the KRAS oncogene..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Nature Communications - 13(2022), 1, Seite 15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andrew Poole [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1038/s41467-022-32811-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01224290X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01224290X | ||
| 003 | DE-627 | ||
| 005 | 20230502064949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-022-32811-1 |2 doi | |
| 035 | |a (DE-627)DOAJ01224290X | ||
| 035 | |a (DE-599)DOAJd2f84672e7fe4eb3b7df368784cf9d36 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Andrew Poole |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering of T cell engaging bispecific protein able to selectively target cancer cells with a high-frequency mutation in the KRAS oncogene. | ||
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Vijaykumar Karuppiah |e verfasserin |4 aut | |
| 700 | 0 | |a Annabelle Hartt |e verfasserin |4 aut | |
| 700 | 0 | |a Jaafar N. Haidar |e verfasserin |4 aut | |
| 700 | 0 | |a Sylvie Moureau |e verfasserin |4 aut | |
| 700 | 0 | |a Tomasz Dobrzycki |e verfasserin |4 aut | |
| 700 | 0 | |a Conor Hayes |e verfasserin |4 aut | |
| 700 | 0 | |a Christopher Rowley |e verfasserin |4 aut | |
| 700 | 0 | |a Jorge Dias |e verfasserin |4 aut | |
| 700 | 0 | |a Stephen Harper |e verfasserin |4 aut | |
| 700 | 0 | |a Keir Barnbrook |e verfasserin |4 aut | |
| 700 | 0 | |a Miriam Hock |e verfasserin |4 aut | |
| 700 | 0 | |a Charlotte Coles |e verfasserin |4 aut | |
| 700 | 0 | |a Wei Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Milos Aleksic |e verfasserin |4 aut | |
| 700 | 0 | |a Aimee Bence Lin |e verfasserin |4 aut | |
| 700 | 0 | |a Ross Robinson |e verfasserin |4 aut | |
| 700 | 0 | |a Joe D. Dukes |e verfasserin |4 aut | |
| 700 | 0 | |a Nathaniel Liddy |e verfasserin |4 aut | |
| 700 | 0 | |a Marc Van der Kamp |e verfasserin |4 aut | |
| 700 | 0 | |a Gregory D. Plowman |e verfasserin |4 aut | |
| 700 | 0 | |a Annelise Vuidepot |e verfasserin |4 aut | |
| 700 | 0 | |a David K. Cole |e verfasserin |4 aut | |
| 700 | 0 | |a Andrew D. Whale |e verfasserin |4 aut | |
| 700 | 0 | |a Chandramouli Chillakuri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Nature Communications |d Nature Portfolio, 2016 |g 13(2022), 1, Seite 15 |w (DE-627)DOAJ000041114 |x 20411723 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g pages:15 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-022-32811-1 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d2f84672e7fe4eb3b7df368784cf9d36 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-022-32811-1 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2041-1723 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |h 15 | ||